Centre Hospitalier Universitaire de Besançon
Besançon, 25000, France
NCT Number: NCT03954470
The aim of this study is to identify typical patterns of renal function evolution in patients with stage 4 chronic kidney disease, regularly followed in nephrology consultation and included in a French cohort.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Besançon, 25000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients should have at least two measurements of GFR <30mL/min/1.73m2 to be included, at least one of them greater than or equal to 15mL/min/1.73m2. The date of the first GFR <30mL/min/ 1.73m2 will be considered as the date of origin.
Exclusion criteria
Time frame: up to 3 years
Time frame: up to 3 years
progression: initiation of an extra-renal purification technique or reduction of GFR of at least 5 mL / min / 1.73m2 compared to inclusion in FAIR-PROGRESS
Centre Hospitalier Universitaire de Besancon
Other
Factors Influencing Risk of Progression of Chronic Kidney Disease in Patients With Severe Renal Failure
Acronym: FAIR-PROGRESS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06094920
Albuminuria, CKD
Almelo, Overijssel, Netherlands
View Trial DetailsNCT06863467
Chronic Disease, Chronic Kidney Disease stage3
Chula Vista, California, United States
View Trial DetailsNCT06037265
Chronic Disease, Chronic Kidney Disease Stage 5
Barranquilla, Atlántico, Colombia
View Trial DetailsNCT05153174
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Rochester, New York, United States
View Trial Details